- Page 1:
TRANSMUCOSAL NASAL DRUG DELIVERY Sy
- Page 5 and 6:
Acknowledgments At the Hospital Pha
- Page 7:
Index EXPERIMENTAL SECTION 5 Projec
- Page 11 and 12:
Summary Summary Transmucosal nasal
- Page 13:
Summary Project III: In this random
- Page 17:
THEORETICAL SECTION
- Page 20 and 21:
1. Nasal drug delivery 1.2 Transmuc
- Page 22 and 23:
1. Nasal drug delivery 1.3 Challeng
- Page 25 and 26:
2. Impact of anatomy and physiology
- Page 27 and 28:
2. Impact of anatomy and physiology
- Page 29 and 30:
2. Impact of anatomy and physiology
- Page 31 and 32:
3. Midazolam 3 Midazolam 3.1 Physic
- Page 33 and 34:
3. Midazolam 3.2.1 Indications and
- Page 35 and 36:
3. Midazolam Administration of high
- Page 37 and 38:
3. Midazolam gastrointestinal tract
- Page 39 and 40:
4. Compounding of nasal midazolam p
- Page 41 and 42:
4. Compounding of nasal midazolam p
- Page 43 and 44:
4. Compounding of nasal midazolam p
- Page 45 and 46:
4. Compounding of nasal midazolam p
- Page 47 and 48:
4. Compounding of nasal midazolam p
- Page 49:
4. Compounding of nasal midazolam p
- Page 53 and 54:
5. Project I: Development of prepar
- Page 55 and 56:
5. Project I: Development of prepar
- Page 57 and 58:
5. Project I: Development of prepar
- Page 59 and 60:
5. Project I: Development of prepar
- Page 61 and 62:
5. Project I: Development of prepar
- Page 63 and 64:
5. Project I: Development of prepar
- Page 65 and 66:
5. Project I: Development of prepar
- Page 67:
5. Project I: Development of prepar
- Page 70 and 71: 6. Project II: Pharmacokinetic of t
- Page 72 and 73: 6. Project II: Pharmacokinetic of t
- Page 74 and 75: 6. Project II: Pharmacokinetic of t
- Page 76 and 77: 6. Project II: Pharmacokinetic of t
- Page 78 and 79: 6. Project II: Pharmacokinetic of t
- Page 80 and 81: 6. Project II: Pharmacokinetic of t
- Page 82 and 83: 6. Project II: Pharmacokinetic of t
- Page 84 and 85: 6. Project II: Pharmacokinetic of t
- Page 86 and 87: 6. Project II: Pharmacokinetic of t
- Page 88 and 89: 6. Project II: Pharmacokinetic of t
- Page 91 and 92: 7. Project III: Transmucosal nasal
- Page 93 and 94: 7. Project III: Transmucosal nasal
- Page 95 and 96: 7. Project III: Transmucosal nasal
- Page 97 and 98: 7. Project III: Transmucosal nasal
- Page 99 and 100: 7. Project III: Transmucosal nasal
- Page 101 and 102: 7. Project III: Transmucosal nasal
- Page 103: 7. Project III: Transmucosal nasal
- Page 106 and 107: 8 Overall discussion pharmacokineti
- Page 108 and 109: 8 Overall discussion considered as
- Page 111: Appendix
- Page 114 and 115: 10 Appendix 10.2 Project I 10.2.1 R
- Page 116 and 117: 10 Appendix 10.2.4 Specification: M
- Page 118 and 119: 10 Appendix 10.2.6 Specification: C
- Page 122 and 123: 10 Appendix 10.2.9 Specification: C
- Page 124 and 125: 10 Appendix Katja Suter-Zimmermann
- Page 126 and 127: 10 Appendix Katja Suter-Zimmermann
- Page 128 and 129: 10 Appendix Katja Suter-Zimmermann
- Page 130 and 131: 10 Appendix Katja Suter-Zimmermann
- Page 132 and 133: 10 Appendix Katja Suter-Zimmermann
- Page 134 and 135: 10 Appendix Katja Suter-Zimmermann
- Page 136 and 137: 10 Appendix Katja Suter-Zimmermann
- Page 138 and 139: 10 Appendix Katja Suter-Zimmermann
- Page 140 and 141: 10 Appendix Katja Suter-Zimmermann
- Page 142 and 143: 10 Appendix Katja Suter-Zimmermann
- Page 144 and 145: 10 Appendix Katja Suter-Zimmermann
- Page 146 and 147: 10 Appendix Katja Suter-Zimmermann
- Page 148 and 149: 10 Appendix Katja Suter-Zimmermann
- Page 150 and 151: 10 Appendix 10.3.2 Case report form
- Page 152 and 153: 10 Appendix Katja Suter-Zimmermann
- Page 154 and 155: 10 Appendix Katja Suter-Zimmermann
- Page 156 and 157: 10 Appendix 10.3.4 Case report form
- Page 158 and 159: 10 Appendix Frequency 10.3.5 Intens
- Page 160 and 161: 10 Appendix 10.3.7 Serumconcentrati
- Page 162 and 163: 10 Appendix Identification midazola
- Page 164 and 165: 10 Appendix Identification midazola
- Page 166 and 167: 10 Appendix Identification midazola
- Page 168 and 169: 10 Appendix 10.3.8 Midazolam serum
- Page 170 and 171:
10 Appendix 10.3.10 Nasal delivery
- Page 172 and 173:
10 Appendix 10.4.2 Case report form
- Page 174 and 175:
10 Appendix 10.4.3 Flowchart: multi
- Page 176 and 177:
10 Appendix Katja Suter-Zimmermann
- Page 178 and 179:
10 Appendix Katja Suter-Zimmermann
- Page 180 and 181:
10 Appendix Katja Suter-Zimmermann
- Page 182 and 183:
10 Appendix Katja Suter-Zimmermann
- Page 185 and 186:
11 References 11 References Abrams,
- Page 187 and 188:
11 References Erjefalt, J.S., I. Er
- Page 189 and 190:
11 References Irie, T. and K. Uekam
- Page 191 and 192:
11 References Malinovsky, J.M., C.
- Page 193 and 194:
11 References Scheepers, M., B. Sch
- Page 195 and 196:
12 Curriculum vitae 12 Curriculum v